Please ensure Javascript is enabled for purposes of website accessibility

This Just In: Is This Analyst Wrong About the Future of MannKind?

By Rich Smith - Jan 6, 2016 at 11:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dueling bankers dispute the drugmaker's bankruptcy prospects.

Wednesday is looking like a very good day for MannKind (MNKD -5.98%) stock -- or a very bad day. It really depends on how you look at it.

Yesterday the maker of Afrezza-brand inhalable insulin announced the termination of its co-marketing alliance with Sanofi (NYSE: SNY) -- less than a year after Sanofi helped bring Afrezza to the retail pharmacy market in the U.S. Afrezza has been approved by the Food and Drug Administration as an inhalable alternative to the insulin diabetics must ordinarily inject into themselves by needle.

But analysts are taking extremely divergent views of the news.

Why this is bad
It almost goes without saying that this is news sounds bad for MannKind -- but one analyst went ahead and said it anyway. In response to the news that Sanofi is bailing out of the partnership, analysts at Piper Jaffray declared their intention to cut MannKind's price target to $0.05 (from its current share price of $0.75). And if "$0.05" sounds to you like "just five cents from zero," there's a reason for that.

Piper thinks MannKind is going bankrupt. Indeed, in its note, Piper even came out and asked (rhetorically) "how the company can avoid bankruptcy," warning that "at best, the company has one year of cash left, assuming it significantly curtails spending." Worse, because "spending is required" to launch a new product, it's almost certain that MannKind will run out of cash faster than that.

Why this is ... good?
And yet, at the same time as Piper was painting this bleak picture, analysts at Griffin Securities are taking a contrary view. As related in StreetInsider.com, these New York bankers argue that ending the alliance with Sanofi was really "the best outcome" for MannKind shareholders, because "the multinational drug company devoted considerably less resources to Afrezza than to its new long-acting insulin, Toujeo."

As fellow Fool Max Macaluso noted, getting Afrezza to market was always going to require "an enormous marketing campaign." And not just that -- doctors and patients are both used to injectable insulins such as Novo Nordisk's (NVO 2.13%) NovoLog, but educating doctors as to Afrezza's safety will cost money, and training patients "to use the inhaler" will cost even more. Yet according to Griffin, "direct-to-consumer advertising has been virtually non-existent" under the Sanofi partnership.

With Sanofi out of the picture, Griffin believes MannKind can now operate with a freer hand, and spend what it needs to win acceptance for Afrezza.

Let's go to the tape
So who's right in this debate? Is it Piper, which values MannKind at just a nickel, or Griffin Securities, which has just upgraded MannKind to buy and assigned a price target nearly 100 times higher ($4 a share)?

I'm afraid our answer is going to be a bit lopsided today.

Here at Motley Fool CAPS, we've been tracking the performance of Piper Jaffray's stock picks since mid-2006. What we've found is that Piper outperforms about 87% of all the other investors we monitor, and has established a winning record in Biotech over the years.

Already one of our best-scoring analysts in pharmaceuticals, Piper Jaffray scores 56% for accuracy on its biotech picks, where it has amassed a record of more than 990 percentage points of market outperformance on over the past decade. Among its winners in biotech and pharma, we find:

Company

 

Piper Jaffray Said:

CAPS Says:

Piper Jaffray's Picks Beating (Lagging) S&P By:

MannKind

Underperform

**

56 points

Novo Nordisk

Outperform

*****

396 points

Regeneron Pharma

Outperform

***

3,184 points (!)

In contrast, our data feeds for Griffin Securities are currently... empty. We know the analyst has been picking stocks for a while, because the recommendations are all right up there on StreetInsider to review (and analyst's three most recent recommendations of Unilife Corporation, Ziopharm, and Intrexon are all down since Griffin picked them). We just don't have hard numbers to confirm our initial observation that Griffin's stock-picking skills seem poor.

The upshot means to investors
So where does this leave investors? One analyst, with an established track record, thinks MannKind is going to zero (or at least heading for the same zip code as zero). The other analyst sees MannKind stock soaring to $4. But that analyst is an unknown quantity.

If you use Motley Fool CAPS as a tool for tuning out noise, and evaluating which analysts' opinions are worth listening to, as I do, the choice here should be clear -- and the numbers we see at MannKind make the choice even clearer.

According to data from S&P Capital IQ, in its entire lifetime as a public company, MannKind has never earned a profit. So far this year, the company has reported losses of more than $90 million, cash burn of nearly $45 million, and thus appears to be burning cash at an annual run-rate of about $60 million.

To feed those fires, MannKind had just under $33 million at the end of September. A recent stock offering probably raised less than $36 million more after fees. My best guess, then, is that the company today probably has no more than $55 million cash on hand -- so Piper is dead on the money when it says MannKind is a year away from running out of money. And Piper could also be right about the risk of bankruptcy.

Even if it sidesteps that risk, though, there's no guarantee MannKind will be able to compete successfully against the likes of Novo Nordisk, which boasts a market cap nearly 500 times as large, $2.5 billion cash in the bank, essentially no debt, a proven product, and a strong 15% growth rate.

Given the available data, I know which analyst I'd be listening to, here. And I know which company I'd pick to win the insulin wars, as well. I suspect you do, too.

Fool contributor Rich Smith does not own shares of, nor is he short, any company named above. You can find him on Motley Fool CAPS, publicly pontificating under the handle TMFDitty, where he's currently ranked No. 298 out of more than 75,000 rated members.

The Motley Fool recommends Novo Nordisk. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$48.66 (-0.86%) $0.42
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
NVO
$104.60 (2.13%) $2.18
MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.09 (-5.98%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.